Lithium (Lithium Carbonate): How This Mood Stabilizer Works, Lab Monitoring, and When Telehealth Helps

Last updated: August 21, 2026

Lithium is one of the oldest and most studied mood stabilizers in psychiatry. It is FDA-approved for bipolar I disorder in adults and children as young as 7, covering both acute manic or mixed episodes and long-term maintenance treatment. Because lithium has a narrow therapeutic window, meaning the effective dose and a potentially toxic dose are closer together than with most other medications, it requires regular blood-level monitoring. This guide covers how lithium works, label dosing ranges, the lab monitoring schedule, side effects and toxicity signs, key drug interactions, and what online psychiatry can and cannot do for lithium patients.

Browse Klarity’s condition pages to see if online care may fit your situation →

See if online mood and depression care may be a fit →

What is lithium and what does it treat?

Lithium is a naturally occurring element used as a prescription mood stabilizer. According to MedlinePlus, lithium is indicated to treat and prevent episodes of mania in people with bipolar disorder. It belongs to a class called antimanic agents and works by decreasing abnormal electrical activity in the brain, though the precise mechanism is still studied.

NAMI describes lithium as a mood stabilizer medication that works in the brain. It is approved for bipolar disorder, also known as manic depression, which involves episodes of depression and mania. Lithium may also be used off-label for depression, particularly when combined with antidepressants.

Per the DailyMed prescribing information for Lithium and Lithium Carbonate (revised 11/2022), FDA-approved indications are:

• Treatment of acute manic and mixed episodes of bipolar I disorder in patients 7 years and older
• Maintenance treatment of bipolar I disorder in patients 7 years and older

MedlinePlus notes that lithium is also sometimes used to treat depression, schizophrenia, impulse control disorders, and certain mental illnesses in children, but these are off-label uses that a clinician documents and discusses based on individual circumstances.

Available forms and brand names

NAMI lists the following formulations and strengths for lithium:

• Tablets: 300 mg
• Capsules: 150 mg, 300 mg, 600 mg
• Extended-release tablets: 300 mg, 450 mg (brand: Lithobid®)
• Oral solution (lithium citrate): 8 mEq per 5 mL

Brand names Eskalith® and Eskalith CR® have been discontinued. Generic lithium carbonate tablets and capsules are widely available. Lithobid® (extended-release tablet) remains on the market. Whether brand or generic is preferred depends on your plan’s formulary; coverage varies by insurer and plan tier, so it is worth verifying benefits before your first fill.

How lithium works

Lithium’s exact mechanism is not fully understood, but it is thought to stabilize neuronal signaling by influencing second-messenger systems in the brain, modulating neurotransmitter release, and affecting ion transport across cell membranes. MedlinePlus states that lithium works by decreasing abnormal activity in the brain.

Clinically, lithium reduces the frequency and severity of both manic and depressive episodes in bipolar I disorder. NAMI notes it may take several weeks to see meaningful changes in symptoms, in practice, clinicians often assess early response at two to four weeks and look for a more complete effect over six to eight weeks.

Typical dosing (label ranges)

Always follow the exact dose on your prescription. Your clinician adjusts the dose based on blood levels, not just weight or symptoms. The following ranges come from the DailyMed prescribing information and NAMI:

• Starting dose, adults and pediatric patients over 30 kg: 300 mg three times daily (tablets or capsules), or 8 mEq (5 mL) of oral solution three times daily
• Starting dose, pediatric patients 20-30 kg: 300 mg twice daily, or 8 mEq (5 mL) oral solution twice daily
• Usual daily dose range (NAMI): 600 mg to 1,200 mg, though some patients require higher doses based on weight, symptoms, and blood levels
• Target serum level for acute mania: 0.8 to 1.2 mEq/L
• Target serum level for maintenance: 0.8 to 1.0 mEq/L

DailyMed notes that a serum lithium concentration assay should be obtained after the first three days of treatment, drawn 12 hours after the last oral dose, then regularly until the patient is stabilized.

Extended-release tablets (Lithobid): swallow whole. Do not split, crush, or chew. MedlinePlus specifies the same instruction. Regular tablets and capsules may be taken with or without food; taking them with food often reduces stomach upset.

Lab monitoring: what to expect and why it matters

Lithium’s narrow therapeutic index is the central clinical challenge. Serum lithium concentrations that treat mania effectively sit close to concentrations that can cause toxicity. This makes regular monitoring non-negotiable, not optional.

The DailyMed label recommends pre-treatment screening for:

• Renal function (lithium is cleared entirely by the kidneys)
• Vital signs and electrolytes
• Thyroid function
• Concurrent medications
• Pregnancy status

NAMI explains that periodically, your clinician will ask for a blood sample to ensure the appropriate level of medication is in your body and to check for side effects such as changes in kidney function or thyroid function.

Ongoing monitoring typically includes:

• Serum lithium levels: Checked after any dose change and at routine intervals (often every three to six months when stable). The 12-hour post-dose draw timing is essential for accurate interpretation, a sample drawn too soon after a dose will falsely appear elevated.
• Kidney function (creatinine, eGFR): DailyMed warns that lithium-induced chronic kidney disease is associated with structural changes in patients on long-term therapy. Kidney monitoring should occur throughout treatment.
• Thyroid function (TSH): NAMI notes that hypothyroidism may occur with long-term lithium use. The DailyMed label also lists hyperthyroidism and hyperparathyroidism as possible complications requiring periodic thyroid and calcium monitoring.
• Calcium: DailyMed flags hypercalcemia and hyperparathyroidism associated with long-term use, with a recommendation to monitor serum calcium.

For a telehealth patient on lithium, labs must be drawn at a local lab or primary care office. A telehealth provider can order the labs, review results, and adjust dosing remotely, but the blood draw itself requires an in-person visit to a lab or clinic.

Common and serious side effects

NAMI lists the following common side effects of lithium:

• Headache
• Nausea, vomiting, or diarrhea
• Dizziness or drowsiness
• Changes in appetite
• Fine hand tremors (especially at higher levels)
• Dry mouth
• Increased thirst and urination
• Hair thinning or hair loss
• Acne-like rash

MedlinePlus adds: restlessness, stomach pain, gas, indigestion, weight change, excessive saliva, joint or muscle pain, and unusual sensitivity to cold.

Many of these side effects are dose-related and improve with lower levels or dose adjustment. Fine hand tremor at the start of treatment often decreases over time. Nausea commonly improves when lithium is taken with food or in extended-release form.

Signs of lithium toxicity, seek care immediately

NAMI is explicit: signs of lithium toxicity include severe nausea and vomiting, severe hand tremors, confusion, vision changes, and unsteadiness while standing or walking. These symptoms need to be addressed immediately with a medical doctor to ensure the lithium level is not dangerously high.

MedlinePlus lists symptoms that require stopping lithium and calling a doctor at once:

• Drowsiness or severe weakness
• Uncontrollable shaking
• Muscle weakness, stiffness, twitching, or tightness
• Loss of coordination
• Diarrhea or vomiting (can accelerate toxicity by causing dehydration)
• Slurred speech
• Ringing in the ears
• Blurred vision
• Blackouts or seizures

Lithium toxicity is a medical emergency. Call 911 or go to the nearest emergency room. Poison control is reachable at 1-800-222-1222.

The DailyMed boxed warning states directly: Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations.

Drug interactions: what raises or lowers lithium levels

Because lithium levels determine both efficacy and toxicity, any drug that raises or lowers the serum level matters clinically. NAMI and DailyMed identify the main categories:

Medications that increase lithium levels (raising toxicity risk)

• Diuretics: hydrochlorothiazide, furosemide (Lasix), bumetanide, torsemide, chlorthalidone, and others. MedlinePlus notes that a clinician may decide against starting lithium if a patient is already on a diuretic, or will monitor closely.
• NSAIDs: ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, and others. NAMI advises avoiding NSAIDs while on lithium. This includes many common over-the-counter pain relievers, acetaminophen (Tylenol) is the preferred alternative for pain management in lithium patients.
• ACE inhibitors and angiotensin receptor blockers (ARBs): enalapril, captopril, lisinopril; valsartan, losartan, olmesartan. Common blood pressure medications in this class can meaningfully raise lithium levels.
• Metronidazole (Flagyl): DailyMed flags this antibiotic as a drug with clinically important interactions that can increase lithium concentrations.
• MAOIs: NAMI lists monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline) as raising lithium levels and effects.
• Serotonergic agents: DailyMed warns of increased serotonin syndrome risk when lithium is co-administered with serotonergic drugs.

Medications that decrease lithium levels

• Caffeine: NAMI notes that caffeine may decrease lithium levels. Conversely, suddenly stopping caffeine can raise levels, talk to your clinician before significantly changing caffeine intake.
• Theophylline (used for breathing problems)
• Sodium (table salt): A low-sodium diet reduces lithium clearance and raises levels, increasing toxicity risk. NAMI specifically advises against low-sodium diets while on lithium.

Antipsychotic combinations

DailyMed warns that there have been reports of neurologic adverse reactions in patients treated with lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome. If you take both a mood stabilizer like lithium and an antipsychotic, your clinician should monitor for encephalopathic symptoms.

Pregnancy and breastfeeding

Lithium requires careful management during pregnancy and breastfeeding. NAMI explains that lithium has been associated with an increased risk of Ebstein’s anomaly, a congenital heart valve defect. Even though data suggest the absolute risk from first-trimester lithium use is low, a fetal cardiac ultrasound is recommended at 16 to 20 weeks of gestation.

NAMI recommends that lithium levels be monitored monthly in early pregnancy and weekly near delivery. DailyMed also flags that dosage adjustments may be needed during pregnancy and the postpartum period, since lithium clearance changes significantly during these phases.

NAMI advises against stopping lithium without first speaking to a clinician: discontinuing mood stabilizer medications during pregnancy has been associated with a significant increase in symptom relapse. Decisions about continuing, adjusting, or switching lithium during pregnancy are made with a prescriber who knows your full history, they are not one-size-fits-all.

Regarding breastfeeding: caution is advised since lithium passes into breast milk. NAMI states that breastfeeding is generally not recommended while taking lithium.

Long-term considerations

NAMI describes bipolar disorder as requiring long-term treatment in most cases. Mood stabilizer treatment is generally needed lifelong for persons with bipolar disorder, and missing doses increases the risk of mood relapse.

The two most important long-term monitoring concerns are:

1. Kidney function: Rare kidney problems have been associated with long-term lithium use, and the risk increases with higher lithium levels. The DailyMed label identifies lithium-induced chronic kidney disease as an established risk, associated with structural changes in the kidneys. Routine monitoring lets your clinician catch early changes before they become significant.
2. Thyroid function: Hypothyroidism may develop over time. It is treatable with thyroid hormone replacement while continuing lithium, so it does not necessarily mean stopping the medication. DailyMed also notes that hyperthyroidism and hyperparathyroidism (elevated calcium) can occur and warrant monitoring.

When telehealth can help, and where its limits are

Online psychiatry through platforms like Klarity connects patients with licensed psychiatrists and psychiatric nurse practitioners who can evaluate, prescribe, and manage a range of psychiatric medications. Klarity has 2,000+ licensed providers across the United States.

For lithium patients, telehealth can be appropriate for:

• Initial psychiatric evaluation and diagnosis of bipolar I disorder
• Ordering baseline labs (renal, thyroid, electrolytes, pregnancy screening) before starting lithium, with the patient going to a local lab for the draw
• Prescribing lithium and titrating the dose based on returned lab results reviewed remotely
• Ongoing medication management for patients who are stable on a consistent lithium dose with a well-established monitoring routine
• Ordering and reviewing periodic lithium serum levels, kidney function panels, and thyroid labs remotely
• Adjusting dose in response to lab changes or side effect reports

Telehealth is not a substitute for in-person or emergency care in these situations:

• Signs of lithium toxicity (confusion, severe tremor, vomiting, loss of coordination), this requires an emergency room visit, not a video call
• Active manic or psychotic episodes severe enough to pose safety risks to the patient or others
• Pregnancy management of lithium near delivery, which requires close coordination with obstetric care
• Significant kidney disease (severe renal impairment: DailyMed recommends avoiding lithium entirely when creatinine clearance is below 30 mL/min), these patients need specialist-level nephrology coordination that goes beyond standard telehealth psychiatry

If you are stable on lithium, already know your dose, and have a routine lab schedule, online psychiatry may offer a convenient way to continue care, refill prescriptions, and review lab results without traveling to a clinic every few months.

Coverage for lithium and psychiatric evaluations varies by insurance plan. Some plans may cover telehealth mental health visits; others require in-network providers or prior authorization for certain medications. Verify your specific benefits before booking. If you have questions about what your plan may cover, browse Klarity’s condition pages to explore your options.

Safety information

If you or someone you know is experiencing a mental health crisis, call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room. For suspected lithium toxicity, call 911 or the Poison Control Center at 1-800-222-1222.

This article is for patient education only. It does not replace a clinical evaluation, and no medication decision should be based on a blog post alone. Always discuss changes to your lithium regimen with your prescriber.

Summary

• Lithium is FDA-approved for acute manic/mixed episodes and maintenance treatment of bipolar I disorder in patients 7 years and older
• Common forms: tablets 300 mg, capsules 150/300/600 mg, extended-release tablets 300/450 mg (Lithobid), oral solution 8 mEq/5 mL
• Starting dose for most adults: 300 mg three times daily; titrated by serum level, not just symptoms
• Target serum levels: 0.8-1.2 mEq/L for acute mania; 0.8-1.0 mEq/L for maintenance
• Boxed warning: lithium toxicity can occur at doses close to therapeutic levels; serum monitoring is mandatory
• Key monitoring: lithium levels, kidney function, thyroid function, calcium
• Major drug interactions: NSAIDs and diuretics raise levels; caffeine and salt may lower them
• Pregnancy: low but real risk of Ebstein’s anomaly; do not stop without clinician guidance
• Telehealth can manage stable lithium patients remotely; lab draws still require an in-person visit; toxicity requires emergency care

Related Klarity articles: Depakote (divalproex): mood stabilizer guide | Lamictal (lamotrigine): mood stabilizer guide | Seroquel (quetiapine): antipsychotic guide